Hims & Hers Health Inc. Stock News

Hims & Hers has experienced a hefty sell-off in recent weeks. This sell-off was mainly caused by short-term turbulence, and I expect the company to resolve these issues in the next quarter. HIMS needs to grow in the mid-teens percentage range for the next few years to justify their current valuation.

Shares of Hims & Hers Health Inc. NYSE: HIMS have been the hottest thing in the medical sector, and for good reason. The company's fundamentals are highly attractive for investors who prefer to acquire growth stories early, before they become too large to price in further expansion.

Telehealth stock Hims & Hers Health Inc (NYSE:HIMS) just suffered a steep pullback after President Donald Trump's said Novo Nordisk's (NVO) weight-loss and diabetes drugs , Wegovy and Ozempic, should be reduced to $150 a month.

Hims & Hers offers a compelling "Buy" opportunity after a 30% pullback, despite recent growth concerns and insider selling. HIMS maintains strong long-term growth targets, aiming for $6.5 billion in revenue and $1.3+ billion in adjusted EBITDA by FY30 (representing ~4x profit expansion from current levels). Current valuation appears more attractive, with HIMS trading at 32.8x EV/FY25 adjusted E...

I expect Hims & Hers Health, Inc. to show stabilizing ARPU around $54+ per user in Q3 despite the GLP-1 slowdown, which could signal meaningful upside to the company's conservative 2030 guidance. I'm anticipating a slight margin dip in Q3. Margins should then stabilize thanks to 1-3% annual marketing leverage gains that support subscriber growth without added costs. In my view, HIMS is already ...

Hims & Hers (HIMS) is emerging as a disruptive force in the obesity treatment market, challenging established GLP-1 drug makers. HIMS has aggressively captured market share, often operating in a legal 'grey area' regarding compounded obesity drugs. Recent FDA policy changes ending temporary compounding allowances raise questions about HIMS's continued ability to offer these treatments.

Hims & Hers Health launched menopause and low testosterone products in the last month, expanding its addressable market and supporting its $6.5 billion 2030 revenue target. Recent product launches, including at-home lab testing, are expected to boost ARPU and drive significant revenue growth for HIMS in coming years. The stock market over reacted to planned stock sells by the CEO.

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.